Please login to the form below

Not currently logged in
Email:
Password:

Medivir appoints Actelion's Henric Juserius to senior commercial role

As executive vice president, commercial he will head up all the company's activities in the area

Medivir has appointed Actelion's Henric Juserius to head up its commercial activities and join its management team.

Juserius will move to the Swedish specialty pharma company in August from Actelion, where he was most recently commercial director for the Nordic region.

He has more than 20 years' experience in pharmaceutical marketing and sales, gained from companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

Maris Hartmanis, Medivir's president and CEO, said: "I am very pleased to welcome Henric Juserius to Medivir as executive vice president, commercial.

“His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435.”

The drug is a novel protease inhibitor in phase III clinical trials for hepatitis C that Medivir is developing in collaboration with Janssen Pharmaceuticals.

Meanwhile, the firm's first product, OTC cold sore treatment Xerese/Xerclear, is approved in Europe, where Medivir is launching it in partnership with GlaxoSmithKline.

15th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics